Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akums Drugs and PharmaceuticalsNSE:AKUMS -2.03%39 Return-on-Tangible-Equity is 10.24% as of Mar. 2026, which is 8% below its 10-year median of 11.12. GuruFocus rates NSE:AKUMS with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 901 Drug Manufacturers companies, Akums Drugs and Pharmaceuticals ranks better than 50.94% on this metric.
The historical rank and industry rank for Akums Drugs and Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
NSE:AKUMS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -34.16 Med: 11.12 Max: 18.1
Current: 8.08
During the past 6 years, Akums Drugs and Pharmaceuticals's highest Return-on-Tangible-Equity was 18.10%. The lowest was -34.16%. And the median was 11.12%.
NSE:AKUMS's Return-on-Tangible-Equity is ranked better than 50.94% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.87
vs NSE:AKUMS: 8.08
Akums Drugs and Pharmaceuticals (NSE:AKUMS) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Akums Drugs and Pharmaceuticals Return-on-Tangible-Equity Related Terms
Akums Drugs and Pharmaceuticals Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akums Drugs and Pharmaceuticals Return-on-Tangible-Equity Chart
NSE:AKUMS vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akums Drugs and Pharmaceuticals Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Akums Drugs and Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.24% mean?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a Return-on-Tangible-Equity of 10.24% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Akums Drugs and Pharmaceuticals and its competitors. This is near median its historical median of 11.12. According to the industry distribution chart, Akums Drugs and Pharmaceuticals ranks #442 out of 901 companies in the Drug Manufacturers industry, placing it in the top 49.1%.
Is Akums Drugs and Pharmaceuticals' Return-on-Tangible-Equity too high?
Akums Drugs and Pharmaceuticals' current Return-on-Tangible-Equity of 10.24% is near median its 10-year median of 11.12. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.87. Akums Drugs and Pharmaceuticals' value of 10.24% is 30.1% above this industry median. Based on the distribution chart, Akums Drugs and Pharmaceuticals ranks #442 out of 901 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Akums Drugs and Pharmaceuticals ranks #442 out of 901 companies for Return-on-Tangible-Equity. This puts Akums Drugs and Pharmaceuticals in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.87. Akums Drugs and Pharmaceuticals' value of 10.24% is 30.1% above this benchmark. While the company's 10-year median is 11.12 vs. the industry median of 7.87, Akums Drugs and Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.87, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akums Drugs and Pharmaceuticals's current Return-on-Tangible-Equity of 10.24% is 30.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Akums Drugs and Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akums Drugs and Pharmaceuticals's current Return-on-Tangible-Equity is 10.24%, which is near median its own 10-year median of 11.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current Return-on-Tangible-Equity of 10.24%. The current Return-on-Tangible-Equity is 10.24%, which is near median its 10-year median of 11.12 and 30.1% above the Drug Manufacturers industry median of 7.87. Akums Drugs and Pharmaceuticals' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current Return-on-Tangible-Equity is 10.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
39GF Score
Get the complete analysis for NSE:AKUMS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AKUMS has been successfully added to your 
